Experience on the Management of Patients with Asthma or Chronic Obstructive Pulmonary Disease During the COVID-19 Pandemic: the NEUMOBIAL Study.
Asthma
COPD
COVID-19
Chronic obstructive pulmonary disease
Telemedicine
Treatment adherence
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
15
07
2022
accepted:
01
09
2022
pubmed:
18
9
2022
medline:
5
10
2022
entrez:
17
9
2022
Statut:
ppublish
Résumé
Chronic obstructive pulmonary disease (COPD) and asthma are treatable but greatly underdiagnosed disorders. Telemedicine made it possible to continue diagnosis, follow-up visits and treatment modifications during the COVID-19 pandemic. The present study describes the management of patients with COPD and asthma, and their treatments during the pandemic from the pulmonologist's perspective. NEUMOBIAL was an ecological study with aggregated data. A total of 279 Spanish pulmonologists answered a 60-question survey about their last 10 patients, focused on the characterisation and changes in visits and treatments during the pandemic. Most pulmonologists (72.0%) considered that the pandemic negatively altered the diagnosis and follow-up of patients with asthma or COPD. Diagnostic tests were reduced during the pandemic, mainly because they were not recommended by pulmonologists (68.1% and 72.7% in the case of COPD and asthma tests, respectively). Moreover, 17.3% of the COPD and 19.1% of the asthma visits were remote visits. According to pulmonologists, low adherence to treatment was mainly due to a lack of patient knowledge about their disease (75.3% and 81.7% in COPD and asthma, respectively). Other factors that also influenced adherence were inadequate use of the inhaler (59.5% for COPD and 57.7% for asthma) and a lack of knowledge about the device (57.3% for COPD and 57.7% for asthma). Pulmonologists chose Zonda According to pulmonologists, during the pandemic, treatments for COPD and asthma were mainly chosen on the basis of their ease of use; treatment adherence was good; and the number of remote visits increased.
Identifiants
pubmed: 36114950
doi: 10.1007/s12325-022-02313-z
pii: 10.1007/s12325-022-02313-z
pmc: PMC9483441
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
5216-5228Informations de copyright
© 2022. The Author(s).
Références
WHO. The top 10 causes of death. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death .
GINA. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2022. www.ginasthma.org .
Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11): e442.
doi: 10.1371/journal.pmed.0030442
Loftus PA, Wise SK. Epidemiology of asthma. Curr Opin Otolaryngol Head Neck Surg. 2016;24(3):245–9.
doi: 10.1097/MOO.0000000000000262
Soriano JB, Alfageme I, Miravitlles M, et al. Prevalence and determinants of COPD in Spain: EPISCAN II. Arch Bronconeumol. 2021;57(1):61–9.
doi: 10.1016/j.arbres.2020.07.024
GOLD. Global initiative for chronic obstructive lung disease. GOLD 2021 2021. https://goldcopd.org/2021-gold-reports/ .
GEMA. Guía Española para el Manejo del Asma. GEMA 5.0 2020. http://www.seicap.es/gu%C3%ADa-gema-5-0_87644.pdf .
Anzueto A, Miravitlles M. Tiotropium in chronic obstructive pulmonary disease—a review of clinical development. Respir Res. 2020;21(1):199.
doi: 10.1186/s12931-020-01407-y
O’Byrne PM, Mejza F. Advances in the treatment of mild asthma: recent evidence. Pol Arch Intern Med. 2018;128(9):545–9.
doi: 10.20452/pamw.4341
Miravitlles M, Calle M, Molina J, et al. Spanish COPD guidelines (GesEPOC) 2021: updated pharmacological treatment of stable COPD. Arch Bronconeumol. 2022;58(1):69–81.
doi: 10.1016/j.arbres.2021.03.005
Peytremann-Bridevaux I, Arditi C, Gex G, Bridevaux PO, Burnand B. Chronic disease management programmes for adults with asthma. Cochrane Database Syst Rev. 2015;5:CD007988.
Tsutsui M, Gerayeli F, Sin DD. Pulmonary rehabilitation in a post-COVID-19 world: telerehabilitation as a new standard in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2021;16:379–91.
doi: 10.2147/COPD.S263031
Lewis A, Knight E, Bland M, et al. Feasibility of an online platform delivery of pulmonary rehabilitation for individuals with chronic respiratory disease. BMJ Open Respir Res. 2021;8(1):e000880.
doi: 10.1136/bmjresp-2021-000880
Hincapie MA, Gallego JC, Gempeler A, Pineros JA, Nasner D, Escobar MF. Implementation and usefulness of telemedicine during the COVID-19 pandemic: a scoping review. J Prim Care Community Health. 2020;11:2150132720980612.
doi: 10.1177/2150132720980612
Ancochea J, Garcia-Rio F, Vazquez-Espinosa E, et al. Efficacy and costs of telehealth for the management of COPD: the PROMETE II trial. Eur Respir J. 2018;51(5):1800354.
doi: 10.1183/13993003.00354-2018
Walker PP, Pompilio PP, Zanaboni P, et al. Telemonitoring in chronic obstructive pulmonary disease (CHROMED). A randomized clinical trial. Am J Respir Crit Care Med. 2018;198(5):620–8.
doi: 10.1164/rccm.201712-2404OC
Jang S, Kim Y, Cho WK. A systematic review and meta-analysis of telemonitoring interventions on severe COPD exacerbations. Int J Environ Res Public Health. 2021;18(13):6757.
doi: 10.3390/ijerph18136757
Barbosa MT, Sousa CS, Morais-Almeida M, Simoes MJ, Mendes P. Telemedicine in COPD: an overview by topics. COPD. 2020;17(5):601–17.
doi: 10.1080/15412555.2020.1815182
Demoly P, Paggiaro P, Plaza V, et al. Prevalence of asthma control among adults in France, Germany, Italy, Spain and the UK. Eur Respir Rev. 2009;18(112):105–12.
doi: 10.1183/09059180.00001209
Soriano JB, Hahsler M, Soriano C, et al. Temporal transitions in COPD severity stages within the GOLD 2017 classification system. Respir Med. 2018;142:81–5.
doi: 10.1016/j.rmed.2018.07.019
Halpin DMG, de Jong HJI, Carter V, Skinner D, Price D. Distribution, temporal stability and appropriateness of therapy of patients with COPD in the UK in relation to GOLD 2019. EClinicalMedicine. 2019;14:32–41.
doi: 10.1016/j.eclinm.2019.07.003
Suissa S, Dell’Aniello S, Ernst P. Comparative effectiveness and safety of LABA-LAMA vs LABA-ICS treatment of COPD in real-world clinical practice. Chest. 2019;155(6):1158–65.
doi: 10.1016/j.chest.2019.03.005
GEMA. Guía Española para el Manejo del Asma. GEMA 5.1 2021. www.gemasma.com
George M, Bender B. New insights to improve treatment adherence in asthma and COPD. Patient Prefer Adherence. 2019;13:1325–34.
doi: 10.2147/PPA.S209532
Plaza V, Lopez-Vina A, Entrenas LM, et al. Differences in adherence and non-adherence behaviour patterns to inhaler devices between COPD and asthma patients. COPD. 2016;13(5):547–54.
doi: 10.3109/15412555.2015.1118449
Monteiro C, Maricoto T, Prazeres F, Augusto Simoes P, Augusto SJ. Determining factors associated with inhaled therapy adherence on asthma and COPD: a systematic review and meta-analysis of the global literature. Respir Med. 2022;191:106724.
doi: 10.1016/j.rmed.2021.106724
Kardas P, Lewek P, Strzondała M. Adherence to treatment in asthma and COPD patients in their doctors’ assessment. Pneumonol Alergol Pol. 2015;83(6):436–44.
pubmed: 26559796
Bourbeau J, Farias R. Making sense of telemedicine in the management of COPD. Eur Respir J. 2018;51(5):1800851.
doi: 10.1183/13993003.00851-2018
Chongmelaxme B, Lee S, Dhippayom T, Saokaew S, Chaiyakunapruk N, Dilokthornsakul P. The effects of telemedicine on asthma control and patients’ quality of life in adults: a systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2019;7(1):199–216 (e11).
doi: 10.1016/j.jaip.2018.07.015
Lopez-Campos JL, Calle M, Cosío BG, et al. Soporte telefónico al paciente con EPOC en tiempos de la COVID-19. Open Respir Archives. 2020;2(3):179–85.
doi: 10.1016/j.opresp.2020.05.009
Davies B, Kenia P, Nagakumar P, Gupta A. Paediatric and adolescent asthma: a narrative review of telemedicine and emerging technologies for the post-COVID-19 era. Clin Exp Allergy. 2021;51(3):393–401.
doi: 10.1111/cea.13836
Portnoy JM, Waller M, De Lurgio S, Dinakar C. Telemedicine is as effective as in-person visits for patients with asthma. Ann Allergy Asthma Immunol. 2016;117(3):241–5.
doi: 10.1016/j.anai.2016.07.012
Persaud YK, Portnoy JM. Ten rules for implementation of a telemedicine program to care for patients with asthma. J Allergy Clin Immunol Pract. 2021;9(1):13–21.
doi: 10.1016/j.jaip.2020.10.005